advertisement
Abstract #15941 Published in IGR 2-3
A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release
Zignani M; Einmahl S; Baeyens V; Varesio E; Veuthey JL; Anderson J; Heller J; Tabatabay C; Gurny REuropean Journal of Pharmaceutics and Biopharmaceutics 2000; 50: 251-255
A viscous hydrophobic poly(ortho ester) (POE) has been developed as a biocompatible, biodegradable sustained release system for selected cases of glaucoma filtering surgery. Dexamethasone and 5-fluorouracil (5-FU) are frequently administered together postoperatively, for their anti- fibroblastic and anti-inflammatory properties, respectively. A combined sustained release of both drugs could be advantageously used. Drug release kinetics were studied using specially designed thermostated cells. Subconjunctival tolerance was evaluated on New Zealand albino rabbits by clinical evaluation. Due to its basicity, the addition of dexamethasone sodium phosphate (DEX-P) stabilized the polymer and prolonged 5-FU in vitro release from two to four days. Both therapeutic agents were released concomitantly, according to a linear profile. The presence of 5-FU only slightly affected the overall subconjunctival tolerance of POE in rabbits, whereas the addition of DEX-P markedly improved POE tolerance by reducing the hyperemia of the conjunctiva to a minimal grade.
Dr. R. Gurny, Department of Pharmaceutics/Biopharmaceutics, School of Pharmacy, University of Geneva, quai Ernest-Ansermet 30, CH-1211 Geneva 4, Switzerland
Classification:
12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
